Natera (NASDAQ:NTRA) Director Sells $642,535.92 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 2,964 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the sale, the director directly owned 3,124 shares in the company, valued at approximately $677,220.72. This represents a 48.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Trading Up 2.9%

Shares of NTRA traded up $6.33 on Wednesday, reaching $226.44. The company’s stock had a trading volume of 1,777,285 shares, compared to its average volume of 1,236,223. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The stock has a market capitalization of $32.43 billion, a PE ratio of -138.92 and a beta of 1.56. The firm has a fifty day moving average of $207.35 and a 200-day moving average of $215.50.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research reports. BTIG Research lowered their price objective on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Evercore reiterated an “outperform” rating and set a $270.00 price target on shares of Natera in a research report on Friday, May 8th. Morgan Stanley dropped their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Finally, William Blair started coverage on shares of Natera in a report on Tuesday, April 14th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.53.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Reflection Asset Management purchased a new stake in shares of Natera in the 4th quarter valued at $29,000. Palladiem LLC acquired a new stake in Natera during the fourth quarter worth about $31,000. Bank of Jackson Hole Trust lifted its stake in Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the last quarter. International Assets Investment Management LLC raised its holdings in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Natera in the 4th quarter valued at $39,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.